Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > New PR

<< Previous

Bullboard Posts

Next >>

Comment by jfm1330on Apr 08, 2022 3:13pm

119 Views

Post# 34588915

RE:RE:RE:RE:RE:RE:RE:RE:New PR

It would be strange to have this PR out with positive comments by Marsolais and absolutely no sign of efficacy in phase Ia while it is close to be completed. I know they would be able to hide behind the excuse that phase Ia is not designed to show efficacy, but it would be surprising given that they are still pushing preclinical data pointing at efficacy against very advanced and resistant cancers involving cancer stem cells.

longterm56 wrote:

Biobob wrote: Great news for Minimouse...

Man .. this crowd is getting ugly!! Hang on, all, we haven't yet heard from those who really know!!!!

-LT